Holen Sie sich die Stockscreener-App
4.86
4.52%
0.21
Vorhandelsmarkt:
4.94
0.08
+1.65%
Schlusskurs vom Vortag:
$4.65
Offen:
$4.58
24-Stunden-Volumen:
117.98K
Relative Volume:
0.48
Marktkapitalisierung:
$53.89M
Einnahmen:
$52.29M
Nettoeinkommen (Verlust:
$-73.52M
KGV:
-7.3636
EPS:
-0.66
Netto-Cashflow:
$-100.45M
1W Leistung:
+9.21%
1M Leistung:
+1.46%
6M Leistung:
-2.21%
1J Leistung:
-51.20%
1-Tages-Spanne:
$4.58
$4.89
1-Wochen-Bereich:
$4.27
$4.89
52-Wochen-Spanne:
$3.61
$11.09
Precision Biosciences Inc Stock (DTIL) Company Profile
Firmenname
Precision Biosciences Inc
Sektor
Branche
Telefon
919-314-5512
Adresse
302 EAST PETTIGREW STREET, DURHAM, NC
Vergleichen Sie DTIL mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DTIL
Precision Biosciences Inc
|
4.86 | 49.34M | 52.29M | -73.52M | -100.45M | -0.66 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Precision Biosciences Inc Stock (DTIL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-01-10 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2024-04-30 | Eingeleitet | Guggenheim | Buy |
| 2022-06-17 | Eingeleitet | BMO Capital Markets | Outperform |
| 2022-06-09 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2020-07-27 | Fortgesetzt | BTIG Research | Buy |
| 2020-04-03 | Herabstufung | Goldman | Buy → Neutral |
| 2020-03-05 | Eingeleitet | Stifel | Buy |
| 2020-02-25 | Eingeleitet | William Blair | Outperform |
| 2019-08-09 | Eingeleitet | BTIG Research | Buy |
| 2019-07-16 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-04-22 | Eingeleitet | Barclays | Overweight |
| 2019-04-22 | Eingeleitet | Goldman | Buy |
| 2019-04-22 | Eingeleitet | JP Morgan | Overweight |
| 2019-04-22 | Eingeleitet | Jefferies | Buy |
Alle ansehen
Precision Biosciences Inc Aktie (DTIL) Neueste Nachrichten
What analysts say about Precision BioSciences Inc. stockConsistently high returns - jammulinksnews.com
What drives Precision BioSciences Inc. stock priceFastest return on investment - jammulinksnews.com
Precision BioSciences Inc. Stock Analysis and ForecastFree Capital Growth Strategies - jammulinksnews.com
Precision BioSciences Secures Orphan Drug Designation for DMD Treatment, DTIL Stock News - AInvest
Precision BioSciences Duchenne muscular dystrophy treatment gets orphan status - TipRanks
Precision BioSciences gets FDA orphan drug designations for DMD treatment By Investing.com - Investing.com Canada
Precision BioSciences reports promising DMD gene editing results By Investing.com - Investing.com Canada
Precision BioSciences Highlights New Preclinical Data for PBGENE-DMD Further Supporting Advancement of Novel Gene Editing Approach for the Treatment of Duchenne Muscular Dystrophy Towards Clinic - Business Wire
How Precision BioSciences Inc. stock performs during market volatilityFree Market Sentiment Analysis - Newser
Precision Bio's DMD Therapy Gets Rare Pediatric Status, But Stock Slides; Retail Crowd Sees ‘Good Risk-Reward’ - MSN
Why Precision BioSciences Inc. stock attracts strong analyst attentionPortfolio Boosting Stock Alerts - Newser
What makes Precision BioSciences Inc. stock price move sharplyTriple Digit Return Forecasts - Newser
(DTIL) Proactive Strategies - news.stocktradersdaily.com
Precision Biosciences CFO Sells Shares to Cover Tax Obligations - TradingView
Precision BioSciences, Inc.(NasdaqCM: DTIL) added to Russell 3000E Value Index - MarketScreener
Insider Buying: Kevin Buehler Acquires Shares of Precision BioSciences Inc (DTIL) - GuruFocus
Precision Biosciences director Brown buys $6963 in DTIL stock - Investing.com
Precision BioSciences stock jumps after FDA grants rare pediatric designation By Investing.com - Investing.com UK
A startup banks $66M to pursue ‘inclusive precision medicine’ - BioPharma Dive
precision biosciences reports voting outcomes at annual shareholder meeting By Investing.com - Investing.com Australia
precision biosciences reports voting outcomes at annual shareholder meeting - Investing.com
Precision BioSciences Holds Annual Stockholder Meeting - TipRanks
Precision BioSciences (DTIL): Rating Reaffirmed at Buy with $60 Target | DTIL Stock News - GuruFocus
Precision BioSciences: Q1 Earnings Snapshot - CT Insider
Precision BioSciences Reports Q1 2025 Financial Results - TipRanks
Transcript : Precision BioSciences, Inc.Special Call - marketscreener.com
Precision BioSciences Inc Reports Q1 2025 EPS of $(2.21) and Rev - GuruFocus
Precision BioSciences Reports Q1 Results and Business Update - TipRanks
Precision BioSciences (DTIL) Reports Q1 Loss, Lags Revenue Estimates - Yahoo Finance
Precision BioSciences (DTIL) Reports Robust Q1 Revenue and Advan - GuruFocus
Precision BioSciences Reports First Quarter 2025 Financial Results and Provides Business Update - BioSpace
Precision BioSciences Reports First Quarter 2025 Financial Resul - GuruFocus
DTIL Reports Strong Start to 2025 with Clinical Progress | DTIL Stock News - GuruFocus
Finanzdaten der Precision Biosciences Inc-Aktie (DTIL)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):